SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sustained rally to a 52-week high and push through a long-watched round-number level are driving attention, with holders celebrating the recovery while skeptics question whether it can hold without a stronger company-specific catalyst. Traders are also watching the upcoming earnings report and pipeline developments for confirmation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are focused on reports that Trump ruled out an immediate U.S. strike on Iran, with many interpreting the news as a possible relief-driven futures bounce while others argue conflict and oil-supply risks are merely delayed. The debate is amplifying an already cautious, volatile outlook ahead of the Fed decision, major tech earnings and inflation data.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus stock-and-warrant offering has intensified concern about shareholder dilution and contributed to a steep selloff, alongside broader weakness in nuclear stocks. Traders are divided between viewing the pullback as a buying opportunity tied to domestic uranium-enrichment demand and worrying that valuation, expansion costs, and execution risks outweigh the long-term HALEU and DOE-contract potential.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

FDA clearance to expand Alpha Taus recurrent glioblastoma REGAIN trial and anticipated follow-up data are driving attention, alongside progress in its pancreatic cancer program. Traders are optimistic about the early GBM signal but acknowledge that it comes from a small cohort and await larger-data validation.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

Discussion is focused on the $17.05 million investor settlement: eligible shareholders are being reminded to file claims before the deadline, with a final approval hearing scheduled immediately afterward. Some traders view clearing the legal overhang as a positive, while others emphasize the settlements limited per-share recovery and historical allegations about Twists production and financial disclosures.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is under pressure as gold has weakened and rising rate expectations and yields weigh on precious metals and miners. Traders are divided between viewing the pullback and nearby support as a buying opportunity and expecting further losses if support gives way.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Volatile natural-gas futures are driving discussion, with traders weighing winter-weather demand and storage reports against mild-weather forecasts, strong production, and ample supply; pipeline and Freeport disruptions have also sparked sharp moves. Views are split on whether gas can sustain a rebound, while many warn that BOILs leveraged futures exposure and decay make it especially risky to hold.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating Iran and broader Middle East tensions could disrupt oil supplies and shipping. Bulls see tight supply and continued geopolitical risk supporting the move, while bears argue the rally may be overextended and could reverse if tensions ease or a deal emerges.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Traders are focused on SQQQ as a leveraged hedge against the Nasdaq, citing tech weakness and concerns that heavy AI spending may not deliver adequate returns, alongside interest-rate and geopolitical risks. Some expect further downside in tech and favor SQQQ, while others caution that its daily leverage can erode value and that a Nasdaq rebound could reverse its gains.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung-cancer results for IMDELLTRA plus Imfinzi are drawing attention, with traders focused on the reported survival benefit and potential to expand the drugs role in earlier treatment. The community views the data as a meaningful pipeline catalyst, though some question how much it will change Amgens broader growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HRMY vs. CSLLY: Which Stock Is the Better Value Option?

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

Should Value Investors Buy CSL Limited (CSLLY) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

CSLLY vs. ACAD: Which Stock Is the Better Value Option?

CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?

CSLLY or ARGX: Which Is the Better Value Stock Right Now?

CSLLY vs. ARGX: Which Stock Is the Better Value Option?

CSLLY or EXAS: Which Is the Better Value Stock Right Now?

CSLLY vs. EXAS: Which Stock Is the Better Value Option?

CSL Limited (CSLLY) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for CSL Limited (CSLLY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

CSL Ltd. - ADR

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$34.60
Prev Close	$34.40
Open	$35.14
Dividend Yield	3.33%
50-Day Moving Average	$31.25
Beta	0.67
Avg. Volume	91,854.00
PE Ratio	-25.57

52-Week High	$35.64
52-Week Low	$16.01
Market Capitalization	$66.42B
EPS (Annual)	-$1.34
Price to Book	4.48
Revenue Per Employee	$543,728.47

Feed

News

Sentiment

Earnings

Fundamentals

Info

CSLLY Fundamentals